Collagen type I alpha 1 chain mRNA (COL1A1 mRNA) (COL1A1 mRNA)

Collagen type I alpha 1 chain (COL1A1) mRNA is the transcript responsible for the synthesis of the pro-alpha1(I) chain, which combines with the pro-alpha2(I) chain to form type I collagen, the most abundant structural protein in the human body (UniProt P02452). This mRNA is primarily expressed by fibroblasts and osteoblasts and is essential for the structural integrity of bone, skin, and tendons (NCBI Gene ID: 1277). In pathological conditions, the dysregulation of COL1A1 mRNA leads to excessive collagen deposition, resulting in tissue fibrosis in organs such as the liver, lungs, and kidneys (PubMed: 31558490). Therapeutic targeting of COL1A1 mRNA using RNA interference (siRNA) or antisense oligonucleotides (ASOs) is an emerging strategy to treat fibrotic diseases by reducing collagen production at the source (ClinicalTrials.gov: NCT02227459). For example, BMS-986263 is a lipid nanoparticle-encapsulated siRNA designed to knockdown COL1A1 mRNA in hepatic stellate cells to treat liver cirrhosis (PubMed: 29453313). While effective in reducing fibrosis, therapeutic interventions must be carefully managed to avoid systemic side effects related to impaired wound healing or bone mineralization.

Other names

Alpha-1 type I collagen mRNACOL1A1 transcriptPro-alpha1(I) collagen mRNACollagen alpha-1(I) chain mRNA

RNA interference (siRNA) or antisense oligonucleotide (ASO) mediated degradation of mRNA to inhibit the translation of collagen type I alpha 1 protein (PubMed: 31558490).